Rezolute Inc. (RZLT)

[Whalatane]

We are up 189% over the last 3 mths . To reduce exposure after this run is simply good risk management .
A large enough sell order to reduce exposure ,can trigger a cascade of stop loss orders .
Market will be looking at near term P2 DME data as next major catalyst .
JMO
Kiwi

Multi-Center, Randomized, Double-Masked, Placebo-Controlled Parallel-Arm Study
o 94 participants enrolled in the US
• Newly diagnosed treatment naïve DME patients
• CST of =320 µm
• BCVA of =78 ETDRS letters (=20/25 on Snellen chart)
o Dosing regimen
• Once daily oral administration for 3 months
• Three active arms (50mg, 200mg, 400mg) compared to placebo
o Study endpoints
• Primary endpoints: safety; change in CST
• Secondary endpoints
• Change in BCVA; change in DRSS; changes in non-study eye
• Repeat dose pharmacokinetics
o Study goals
• Improvement vs placebo in CST, BCVA
• Dose-response
• Binocular (2-eye) composite responses
o Topline data expected Q2 2024